(Q53694062)
Statements
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. (English)
William R Hiatt
Eric P Brass
Leslie T Cooper
Roger E Morgan
25 November 2011
55
2
381-389.e1